Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma

Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma

BACKGROUND Surgery remains the frontline therapy for patients with localized clear cell renal cell carcinoma (ccRCC); however, 20%–40% recur. Angiogenesis inhibitors have improved survival in metastatic patients and may result in responses in the neoadjuvant setting. The impact of these agents on th...

Full description

Bibliographic Details
Main Authors: Christopher G. Wood, James E. Ferguson III, Joel S. Parker, Dominic T. Moore, Jennifer G. Whisenant, Susan J. Maygarden, Eric M. Wallen, William Y. Kim, Mathew I. Milowsky, Kathryn E. Beckermann, Nancy B. Davis, Scott M. Haake, Jose A. Karam, Dante S. Bortone, Benjamin G. Vincent, Thomas Powles, W. Kimryn Rathmell
Format: Article
Language:English
Published: American Society for Clinical investigation 2020-11-01
Series:JCI Insight
Subjects:
Clinical trials
Oncology
Online Access:https://doi.org/10.1172/jci.insight.132852

Internet

https://doi.org/10.1172/jci.insight.132852

Similar Items